IGF2BP2 and lip and oral cavity carcinoma: Targeting the regulatory mechanism of IGF2BP2 may promote the development of new therapeutic strategies for diabetes [46], fatty liver [22], and pancreatic [47], liver [31], breast [13, 48], and oral cancers [21].